Konstantinos Tripodis, MD
Psychiatry · Burbank, CANPI 1588698534
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $909,573 of the $1,036,705 with a category attached, or 87.7%. 12 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 34.7% of the total. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,050 payments — averaging $987.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$359K
- Alkermes, Inc.$182K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$161K
- Teva Pharmaceuticals USA, Inc.$125K
- Otsuka America Pharmaceutical, Inc.$122K
- Johnson & Johnson$66K
- plus $21K from 6 others
What the payments were for
- Consulting fees$43,5774%
- Speaking & faculty fees$909,57388%
- Travel & lodging$49,2985%
- Food & beverage$34,1633%
- Education$940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 330 | $359,428 |
| Alkermes, Inc. | 182 | $182,144 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 150 | $160,934 |
| Teva Pharmaceuticals USA, Inc. | 109 | $125,208 |
| Otsuka America Pharmaceutical, Inc. | 124 | $122,070 |
| Johnson & Johnson | 114 | $66,213 |
| AbbVie | 21 | $16,749 |
| Sunovion Pharmaceuticals Inc. | 6 | $3,025 |
| E.r. Squibb & Sons, L.L.C. | 6 | $481 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $241 |
| Janssen Scientific Affairs, LLC | 2 | $150 |
| Lundbeck LLC | 3 | $61 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$622,689
- INGREZZA$356,428
- CAPLYTA$159,089
- ARISTADA INITIO$155,672
- ABILIFY MAINTENA$121,089
- UZEDY$118,030
- LYBALVI$96,393
- ABILIFY ASIMTUFII$74,876
- SPRAVATO$37,523
- INVEGA SUSTENNA$26,488
- INVEGA TRINZA$25,479
- VRAYLAR$16,485
- AUSTEDO$3,779
- LATUDA$2,913
- REXULTI$1,444
- Austedo XR$1,225
- COBENFY$385
- INVEGA$147
How this compares
$1,036,705 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 81 | $671,371 |
| Invega TrinzaPaliperidone Palmitate | 23 | $188,631 |
| AristadaAripiprazole Lauroxil | 53 | $143,555 |
| LybalviOlanzapine/Samidorphan Malate | 39 | $58,032 |
| CaplytaLumateperone Tosylate | 35 | $54,464 |
| Invega SustennaPaliperidone Palmitate | 13 | $29,949 |
| Clozapine | 105 | $6,988 |
| Asenapine Maleate | 40 | $4,280 |
| Lamotrigine OdtLamotrigine | 13 | $3,246 |
| Divalproex Sodium ErDivalproex Sodium | 92 | $2,188 |
| Bupropion XlBupropion Hcl | 148 | $1,507 |
| Quetiapine Fumarate | 114 | $1,091 |
| Aripiprazole | 70 | $1,045 |
| Olanzapine | 106 | $1,035 |
| Lorazepam | 103 | $816 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $359,428 | $671,37181 claims |
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $66,213 | $218,58036 claims |
| Alkermes, Inc.Aristada, Lybalvi | $182,144 | $201,58692 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $160,934 | $54,46435 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Burbank
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Jason BermakSan Rafael$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.